Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
14.04
-0.46 (-3.17%)
Mar 13, 2025, 4:00 PM EST - Market closed

Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $601.75 million. The enterprise value is $548.15 million.

Market Cap 601.75M
Enterprise Value 548.15M

Important Dates

The next estimated earnings date is Tuesday, May 6, 2025, before market open.

Earnings Date May 6, 2025
Ex-Dividend Date n/a

Share Statistics

Beta Bionics has 42.86 million shares outstanding.

Current Share Class 42.86M
Shares Outstanding 42.86M
Shares Change (YoY) n/a
Shares Change (QoQ) +23.74%
Owned by Insiders (%) 3.16%
Owned by Institutions (%) 13.24%
Float 41.34M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.00
Forward PS 7.45
PB Ratio 18.31
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 10.34
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.22.

Current Ratio 4.62
Quick Ratio 3.82
Debt / Equity 0.22
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -711.95

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) n/a
Return on Capital Employed (ROCE) -51.33%
Revenue Per Employee $182,247
Profits Per Employee -$190,708
Employee Count 291
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) 15.62
Average Volume (20 Days) 343,711

Short Selling Information

The latest short interest is 945,109, so 2.21% of the outstanding shares have been sold short.

Short Interest 945,109
Short Previous Month 209,284
Short % of Shares Out 2.21%
Short % of Float 2.29%
Short Ratio (days to cover) 0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $53.03 million and -$55.50 million in losses. Loss per share was -$4.89.

Revenue 53.03M
Gross Profit 29.26M
Operating Income -40.58M
Pretax Income -55.50M
Net Income -55.50M
EBITDA -39.37M
EBIT -40.58M
Loss Per Share -$4.89
Full Income Statement

Balance Sheet

The company has $60.90 million in cash and $7.30 million in debt, giving a net cash position of $53.60 million or $1.25 per share.

Cash & Cash Equivalents 60.90M
Total Debt 7.30M
Net Cash 53.60M
Net Cash Per Share $1.25
Equity (Book Value) 32.87M
Book Value Per Share -34.35
Working Capital 64.68M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$40.34 million and capital expenditures -$3.15 million, giving a free cash flow of -$43.49 million.

Operating Cash Flow -40.34M
Capital Expenditures -3.15M
Free Cash Flow -43.49M
FCF Per Share -$1.01
Full Cash Flow Statement

Margins

Gross margin is 55.17%, with operating and profit margins of -76.52% and -104.64%.

Gross Margin 55.17%
Operating Margin -76.52%
Pretax Margin -104.64%
Profit Margin -104.64%
EBITDA Margin -74.24%
EBIT Margin -76.52%
FCF Margin n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -9.22%
FCF Yield -7.23%

Analyst Forecast

The average price target for Beta Bionics is $26.67, which is 89.96% higher than the current price. The consensus rating is "Strong Buy".

Price Target $26.67
Price Target Difference 89.96%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Beta Bionics has an Altman Z-Score of -4.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.06
Piotroski F-Score 1